Anteris Technologies GlobalAVR -5.00%23 EV-to-FCF is -7.85 as of Jun. 26, 2026. GuruFocus rates AVR with a GF Score™ of 23/100. The stock has 7 warning signs investors should review. Among 421 Medical Devices & Instruments companies, Anteris Technologies Global ranks worse than 237529.45% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Anteris Technologies Global's Enterprise Value is $681.77 Mil.
Anteris Technologies Global's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-86.88 Mil. Therefore, Anteris Technologies Global's EV-to-FCF for today is -7.85.
The historical rank and industry rank for Anteris Technologies Global's EV-to-FCF or its related term are showing as below:
AVR'
s EV-to-FCF Range Over the Past 10 Years
Min: -7.85 Med: -1.93 Max: -0.32
Current: -7.85
During the past 13 years, the highest EV-to-FCF of Anteris Technologies Global was -0.32. The lowest was -7.85. And the median was -1.93.
AVR's EV-to-FCF is ranked worse than 100% of 421
companies
in the Medical Devices & Instruments industry
Industry Median: 22.82
vs AVR: -7.85
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Anteris Technologies Global (NAS:AVR) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Anteris Technologies Global's PE Ratio (TTM) for today is calculated as:
Anteris Technologies Global's share price for today is $9.87.
Anteris Technologies Global's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.230.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Anteris Technologies Global EV-to-FCF Related Terms
Anteris Technologies Global EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Anteris Technologies Global's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anteris Technologies Global EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Anteris Technologies Global's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Anteris Technologies Global's EV-to-FCF falls into.
Anteris Technologies Global's current Enterprise Value is $681.77 Mil.
Anteris Technologies Global's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-86.88 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anteris Technologies Global (AVR) has a EV-to-FCF of -7.85 as of Jun. 26, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Anteris Technologies Global and its competitors. According to the industry distribution chart, Anteris Technologies Global ranks #999999 out of 421 companies in the Medical Devices & Instruments industry.
Is Anteris Technologies Global's EV-to-FCF too high?
Anteris Technologies Global's current EV-to-FCF is -7.85. Based on the distribution chart, Anteris Technologies Global ranks #999999 out of 421 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Anteris Technologies Global has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Anteris Technologies Global's EV-to-FCF compare to INMD and QDEL?
According to the Medical Devices & Instruments industry distribution chart, Anteris Technologies Global ranks #999999 out of 421 companies for EV-to-FCF. This places Anteris Technologies Global in the lower half of its industry. The industry median EV-to-FCF is 22.82. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 22.82, based on 421 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Anteris Technologies Global and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 22.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anteris Technologies Global's current EV-to-FCF is -7.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anteris Technologies Global stock overvalued right now?
Anteris Technologies Global (AVR) has a current EV-to-FCF of -7.85. The current EV-to-FCF is -7.85. Anteris Technologies Global's overall GF Score™ is 23/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Anteris Technologies Global (AVR), the current EV-to-FCF is -7.85 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anteris Technologies Global Corp is a structural heart company focused on advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function. Its key product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with interventional cardiologists and cardiac surgeons to treat Aortic Stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. The balloon-expandable DurAVR THV is a biomimetic valve designed to mimic the performance of a healthy human aortic valve and replicate normal aortic blood flow. The company operates in United States, Germany, Australia, Switzerland, and Sweden, with the majority of its revenue generated from the United States.
23GF Score
Get the complete analysis for AVR
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVR has been successfully added to your 
